Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7979522 | 0.86 | HDAC4 (0.58) | KDM4EPOLBRAB9ASMN1; SMN2GAA | |
| SCHEMBL1587164 | 0.84 | KDM4E (0.51) | KDM4EPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27547515 | 0.82 | GAA (0.54) | KDM4EPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12124267 | 0.81 | POLB (0.65) | KDM4EPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6360616 | 0.81 | GSK3B (0.53) | KDM4EPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13636798 | 0.79 | KDM4E (0.50) | KDM4EPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12313385 | 0.79 | RAB9A (0.60) | KDM4EPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6362178 | 0.79 | MAPK1 (0.69) | KDM4EPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6362085 | 0.79 | GAA (0.75) | KDM4EPOLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6978678 | 0.78 | KDM4E (0.49) | KDM4EPOLBRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934264-B1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6313302-B2 | OPIOID KAPPA RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; ANALGESICS, ANTIINFLAMMATORY AGENTS, ANESTHETICS, AND NEUROPROTECTANTS | PFIZER INC. | 2001-11-06 | — | — | US | disclosed |
| US-6310061-B2 | OPIOID RECEPTOR SUBTYPE KAPPA; USE AS ANALGESIC, ANESTHETIC, ANTIINFLAMMATORY OR NEUROPROTECTIVE AGENT, FOR TREATMENT OF ARTHRITIS, STROKE OR FUNCTIONAL BOWEL DISEASE; REDUCED DRUG DEPENDENCY SIDE EFFECTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| US-6307061-B2 | USEFUL AS AN ANALGESIC, ANESTHETIC, ANTI-INFLAMMATORY OR NEUROPROTECIVE AGENT | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6303602-B1 | USEFUL AS ANALGESIC, ANESTHETIC, ANTI-INFLAMMATORY OR NEUROPROTECTIVE AGENT, OR FOR THERAPY OF ARTHRITIS, STROKE OF FUNCTIONAL BOWEL DISEASE | PFIZER INC. | 2001-10-16 | — | — | US | disclosed |
| US-6294557-B1 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-6294569-B2 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | ITO FUMITAKA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-20010014683-A1 | Analgesics; side effect reduction | ITO FUMITAKA (JP) | 2001-08-16 | — | — | US | disclosed |
| US-20010011091-A1 | Analgesics | ITO FUMITAKA (JP) | 2001-08-02 | — | — | US | disclosed |
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | ITO FUMITAKA (JP) | 2001-07-26 | — | — | US | disclosed |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | ITO FUMITAKA (JP) | 2001-07-19 | — | — | US | disclosed |
| US-6201007-B1 | OPIOID KAPPA RECEPTOR AGONISTS; ANALGESICS, ANESTHETICS, NEUROPROTECTIVE AND ANTIINFLAMMATORY AGENTS; STROKES, GASTROINTESTINAL DISORDERS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
| EP-0934264-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998012177-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (JP) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | OPRL1, OPRD1, OPRK1 | KDM4E 2230/4885POLB 2910/4885RAB9A 4821/4885 |
| US-20010011091-A1 | Analgesics | OPRL1, OPRK1, OPRD1 | KDM4E 1759/4885POLB 2807/4885RAB9A 4425/4885 |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | OPRK1, OPRL1, OPRD1 | KDM4E 1781/4885POLB 1022/4885RAB9A 3867/4885 |
| US-20010014683-A1 | Analgesics; side effect reduction | OPRL1, OPRK1, OPRD1 | KDM4E 1884/4885POLB 1996/4885RAB9A 4339/4885 |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | OPRL1, NAP1L1, OPRK1 | KDM4E 2860/4885POLB 2321/4885RAB9A 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.